Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains

15Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The post-β-lactamase-inhibitor effect (PBLIE) of tazobactam combined with ceftolozane was evaluated by time-kill assays on two clinical Escherichia coli strains producing CTX-M-15 with or without TEM-1. The organisms were exposed (2 h) to 4 μg/ml/4 μg/ml of ceftolozane-tazobactam (4x MIC), 4 μg/ml of ceftolozane, and medium containing no drug, washed, and resuspended in medium alone or medium containing ceftolozane-tazobactam or ceftolozane. The PBLIE was determined as 1.3 to 2.1 h, and a postantibiotic effect was measured as 0.8 to 0.9 h. Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Sader, H. S., Rhomberg, P. R., & Jones, R. N. (2014). Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains. Antimicrobial Agents and Chemotherapy, 58(4), 2434–2437. https://doi.org/10.1128/AAC.02398-13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free